Comparative Pharmacology
Head-to-head clinical analysis: KETALAR versus PROPOFOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETALAR versus PROPOFOL.
KETALAR vs PROPOFOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Noncompetitive NMDA receptor antagonist; inhibits glutamate activity, modulates opioid receptors, and interacts with other neurotransmitter systems.
Propofol enhances the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to increased chloride conductance, neuronal hyperpolarization, and anesthetic effects. It also inhibits N-methyl-D-aspartate (NMDA) receptors and modulates calcium influx via L-type calcium channels.
1-4.5 mg/kg IV or 6.5-13 mg/kg IM for induction of anesthesia; 0.1-0.5 mg/kg/min IV infusion for maintenance.
Induction: 2-2.5 mg/kg IV bolus. Maintenance: 25-75 mcg/kg/min IV infusion. For sedation: 25-100 mcg/kg/min IV.
None Documented
None Documented
Clinical Note
moderatePropofol + Torasemide
"The risk or severity of adverse effects can be increased when Propofol is combined with Torasemide."
Clinical Note
moderatePropofol + Etacrynic acid
"The risk or severity of adverse effects can be increased when Propofol is combined with Etacrynic acid."
Clinical Note
moderatePropofol + Furosemide
"The risk or severity of adverse effects can be increased when Propofol is combined with Furosemide."
Clinical Note
moderatePropofol + Bumetanide
Terminal elimination half-life: 2.5-3 hours (ketamine); norketamine: 12 hours. Clinical context: Short half-life facilitates rapid recovery, but context-sensitive half-life increases with infusion duration.
Terminal elimination half-life: 4-7 hours (after prolonged infusion, context-sensitive half-life increases up to 60 minutes after 8-hour infusion).
Renal: 90% as metabolites (norketamine, dehydronorketamine); unchanged: 2-4%. Fecal: <3%.
Renal: <1% unchanged; hepatic metabolism to inactive glucuronide and sulfate conjugates, excreted renally (≈88%) and fecally (≈1-2%).
Category C
Category A/B
General Anesthetic
General Anesthetic
"The risk or severity of adverse effects can be increased when Propofol is combined with Bumetanide."